div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 12button div class=ts-image amp-img class=ts-thumb alt=Page 12: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails12jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 13button div class=ts-image amp-img class=ts-thumb alt=Page 13: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails13jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 14button div class=ts-image amp-img class=ts-thumb alt=Page 14: Benefit-risk assessment of Tegaserod in irritable bowel syndrome src=https:reader031vdocumentsnetreader031viewer2022020213586b5af21a28abf7678ba169html5thumbnails14jpg width=142 height=106 layout=responsive amp-img divdiv